This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining a clinician's confidence in botox biosimilar clinical development programs

Ticker(s): VTRSV, AGN, RVNC

Who's the expert?

Institution: Private Practice

  • Founder of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser and Rejuvenation Center and Tennessee Clinical Research Center located in Nashville, TN as well as being a Clinical Assistant Professor at Vanderbilt University School of Medicine
  • Speaks on national and international fronts, focusing on dermatology issues related to the use of lasers and energy-based devices, as well as the use of fillers and toxins in aesthetic and cosmetic dermatology, lecturing in venues around the world and is a sought-after contributor to educational meetings globally.
  • Author of more than 200 published scientific articles, 10 textbook chapters and the editor of a new textbook on photodynamic therapy

Interview Questions

Based on your experience, what is the demand for botox biosimilars in the market? Other than cost, are there other advantages to the development of a botox biosimilar?

Added By: pharmaadvisor

Based on your knowledge of the market/space, what is the current development status of Viatris/Revance development of their respective botox biosimilar (onabotulinumtoxinA ) and Aquavit's molecule (DTX-021 or 'Dermatox")? What are the companies' clinical development strategies (IND, 351K pathway, etc)?

Added By: pharmaadvisor

For those companies considering the 351K FDA approval pathway for botox biosimilars, how are they addressing FDA requirements to demonstrate similarity, including PK data? Are there potential problems you believe may inhibit these molecules from receiving FDA approval using the 351K pathway?

Added By: pharmaadvisor

What indications are companies planning to pursue each of their initial botox biosimilars? In your opinion, what other clinical trials will be required to expand indications?

Added By: pharmaadvisor

What other challenges do you anticipate companies will encounter with both approval and post-approval uptake?

Added By: pharmaadvisor

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.